LeMaitre Vascular (LMAT) Stock Forecast, Price Target & Predictions
LMAT Stock Forecast
LeMaitre Vascular stock forecast is as follows: an average price target of $81.67 (represents a -8.94% downside from LMAT’s last price of $89.69) and a rating consensus of 'Buy', based on 2 wall street analysts offering a 1-year stock forecast.
LMAT Price Target
The average price target for LeMaitre Vascular (LMAT) is $81.67 based on 1-year price targets from 2 Wall Street analysts in the past 3 months, with a price target range of $100.00 to $70.00. This represents a potential -8.94% downside from LMAT's last price of $89.69.
LMAT Analyst Ratings
According to 2 Wall Street analysts, LeMaitre Vascular's rating consensus is 'Buy'. The analyst rating breakdown for LMAT stock is 0 'Strong Buy' (0.00%), 2 'Buy' (100.00%), 0 'Hold' (0.00%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).
LeMaitre Vascular Price Target by Analyst
| Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
|---|---|---|---|---|---|---|
| Aug 20, 2024 | Daniel Stauder | JMP Securities | $100.00 | $85.53 | 16.92% | 11.50% |
| Apr 26, 2024 | Rick Wise | Stifel Nicolaus | $75.00 | $65.46 | 14.57% | -16.38% |
| Sep 06, 2023 | Suraj Kalia | Oppenheimer | $70.00 | $56.71 | 23.44% | -21.95% |
The latest LeMaitre Vascular stock forecast, released on Aug 20, 2024 by Daniel Stauder from JMP Securities, set a price target of $100.00, which represents a 16.92% increase from the stock price at the time of the forecast ($85.53), and a 11.50% increase from LMAT last price ($89.69).
LeMaitre Vascular Price Target by Period
| 1M | 3M | 12M | |
|---|---|---|---|
| # Anlaysts | 1 | 1 | 2 |
| Avg Price Target | $100.00 | $100.00 | $87.50 |
| Last Closing Price | $89.69 | $89.69 | $89.69 |
| Upside/Downside | 11.50% | 11.50% | -2.44% |
In the current month, the average price target of LeMaitre Vascular stock is $100.00, according to 1 Wall Street analyst offering twelve months forecast. The average price target represents a 11.50% increase as opposed to LeMaitre Vascular's last price of $89.69. This month's average price target is down 0.00% compared to last quarter, and up 14.29% compared to last year.
Analyst Ratings Upgrades/Downgrades
| Date | Company | Previous Rating | New Rating | Rating Change |
|---|---|---|---|---|
| Aug 20, 2024 | JMP Securities | Outperform | Outperform | Hold |
| May 03, 2024 | JMP Securities | Outperform | Outperform | Hold |
| Sep 06, 2023 | Oppenheimer | - | Outperform | Initialise |
LeMaitre Vascular's last stock rating was published by JMP Securities on Aug 20, 2024. The company gave LMAT a "Outperform" rating, the same as its previous rate.
LeMaitre Vascular Financial Forecast
LeMaitre Vascular Revenue Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | $47.41M | $50.12M | $47.08M | $40.95M | $39.03M | $42.11M | $39.56M | $39.50M | $38.37M | $40.67M | $35.88M | $37.55M | $36.42M | $24.85M | $30.55M | $30.17M | $29.10M |
| Avg Forecast | $76.69M | $74.29M | $71.98M | $69.73M | $60.70M | $58.19M | $60.75M | $58.04M | $55.35M | $53.49M | $54.98M | $51.50M | $49.01M | $47.53M | $48.08M | $43.54M | $41.00M | $40.01M | $41.39M | $38.65M | $39.64M | $39.05M | $39.57M | $35.19M | $35.58M | $31.62M | $17.12M | $30.84M | $30.43M | $28.15M |
| High Forecast | $77.96M | $75.53M | $73.17M | $70.89M | $61.71M | $59.16M | $61.76M | $59.01M | $56.27M | $54.28M | $55.90M | $52.36M | $49.67M | $48.32M | $48.88M | $44.26M | $41.68M | $40.67M | $42.11M | $39.32M | $40.33M | $39.72M | $40.26M | $35.80M | $36.20M | $32.17M | $17.42M | $31.37M | $30.96M | $28.64M |
| Low Forecast | $75.37M | $73.02M | $70.74M | $68.53M | $59.65M | $57.19M | $59.71M | $57.05M | $54.40M | $52.47M | $54.04M | $50.62M | $48.85M | $46.71M | $47.26M | $42.79M | $40.29M | $39.32M | $40.46M | $37.79M | $38.75M | $38.17M | $38.68M | $34.40M | $34.78M | $30.91M | $16.74M | $30.15M | $29.75M | $27.52M |
| # Analysts | 3 | 3 | 3 | 3 | 4 | 4 | 4 | 4 | 3 | 6 | 3 | 4 | 7 | 5 | 6 | 3 | 2 | 2 | 2 | 2 | 3 | 4 | 5 | 6 | 11 | 15 | 9 | 9 | 8 | 8 |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | 1.00% | 1.04% | 1.08% | 1.00% | 0.98% | 1.02% | 1.02% | 1.00% | 0.98% | 1.03% | 1.02% | 1.06% | 1.15% | 1.45% | 0.99% | 0.99% | 1.03% |
LeMaitre Vascular's average Quarter revenue forecast for Dec 23 based on 7 analysts is $49.01M, with a low forecast of $48.85M, and a high forecast of $49.67M. LMAT's average Quarter revenue forecast represents a 3.37% increase compared to the company's last Quarter revenue of $47.41M (Sep 23).
LeMaitre Vascular EBITDA Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 3 | 3 | 3 | 3 | 4 | 4 | 4 | 4 | 3 | 6 | 3 | 4 | 7 | 5 | 6 | 3 | 2 | 2 | 2 | 2 | 3 | 4 | 5 | 6 | 11 | 15 | 9 | 9 | 8 | 8 |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | - | $9.37M | $9.63M | $8.91M | $7.80M | $6.41M | $9.06M | $8.04M | $11.31M | $11.98M | $13.59M | $10.69M | $12.04M | $12.73M | $6.47M | $5.82M | $6.63M | $7.24M |
| Avg Forecast | $16.35M | $15.84M | $15.34M | $14.86M | $12.94M | $12.40M | $12.95M | $12.37M | $11.80M | $11.40M | $11.72M | $13.13M | $10.45M | $10.13M | $10.25M | $11.94M | $8.74M | $16.10M | $8.82M | $10.85M | $8.45M | $8.32M | $8.44M | $10.30M | $7.59M | $6.74M | $3.65M | $5.43M | $6.49M | $6.00M |
| High Forecast | $16.62M | $16.10M | $15.60M | $15.11M | $13.15M | $12.61M | $13.17M | $12.58M | $11.99M | $11.57M | $11.92M | $15.76M | $10.59M | $10.30M | $10.42M | $14.32M | $8.89M | $19.32M | $8.98M | $13.02M | $8.60M | $8.47M | $8.58M | $12.36M | $7.72M | $6.86M | $3.71M | $6.52M | $6.60M | $6.11M |
| Low Forecast | $16.07M | $15.57M | $15.08M | $14.61M | $12.72M | $12.19M | $12.73M | $12.16M | $11.60M | $11.19M | $11.52M | $10.50M | $10.41M | $9.96M | $10.07M | $9.55M | $8.59M | $12.88M | $8.63M | $8.68M | $8.26M | $8.14M | $8.25M | $8.24M | $7.41M | $6.59M | $3.57M | $4.34M | $6.34M | $5.87M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | 0.92% | 0.94% | 0.75% | 0.89% | 0.40% | 1.03% | 0.74% | 1.34% | 1.44% | 1.61% | 1.04% | 1.59% | 1.89% | 1.77% | 1.07% | 1.02% | 1.21% |
7 analysts predict LMAT's average Quarter EBITDA for Dec 23 to be $10.45M, with a high of $10.59M and a low of $10.41M. This is 11.51% upper than LeMaitre Vascular's previous annual EBITDA (Sep 23) of $9.37M.
LeMaitre Vascular Net Income Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 3 | 3 | 3 | 3 | 4 | 4 | 4 | 4 | 3 | 6 | 3 | 4 | 7 | 5 | 6 | 3 | 2 | 2 | 2 | 2 | 3 | 4 | 5 | 6 | 11 | 15 | 9 | 9 | 8 | 8 |
| Net Income | - | - | - | - | - | - | - | - | - | - | - | - | - | $7.50M | $8.10M | $6.04M | $5.63M | $5.46M | $3.52M | $6.04M | $6.17M | $6.50M | $8.30M | $5.93M | $7.03M | $7.51M | $3.50M | $3.17M | $4.61M | $5.18M |
| Avg Forecast | $13.86M | $12.27M | $14.09M | $12.04M | $12.16M | $11.29M | $12.57M | $11.14M | $10.33M | $9.87M | $10.72M | $7.57M | $8.08M | $7.02M | $7.19M | $6.88M | $5.81M | $8.74M | $5.77M | $6.25M | $6.96M | $7.39M | $7.99M | $5.71M | $6.67M | $4.41M | $151.51K | $2.96M | $5.16M | $4.74M |
| High Forecast | $14.16M | $12.54M | $14.39M | $12.30M | $12.42M | $11.53M | $12.85M | $11.38M | $10.55M | $10.10M | $10.95M | $9.08M | $8.26M | $7.17M | $7.35M | $8.25M | $5.94M | $10.49M | $5.90M | $7.50M | $7.12M | $7.55M | $8.17M | $6.85M | $6.82M | $4.51M | $154.93K | $3.55M | $5.28M | $4.85M |
| Low Forecast | $13.55M | $12.00M | $13.77M | $11.78M | $11.89M | $11.03M | $12.29M | $10.89M | $10.10M | $9.42M | $10.48M | $6.05M | $7.86M | $6.86M | $7.03M | $5.50M | $5.68M | $6.99M | $5.60M | $5.00M | $6.76M | $7.17M | $7.76M | $4.57M | $6.47M | $4.28M | $147.09K | $2.37M | $5.01M | $4.60M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | 1.07% | 1.13% | 0.88% | 0.97% | 0.62% | 0.61% | 0.97% | 0.89% | 0.88% | 1.04% | 1.04% | 1.06% | 1.70% | 23.10% | 1.07% | 0.89% | 1.09% |
LeMaitre Vascular's average Quarter net income forecast for Dec 23 is $8.08M, with a range of $7.86M to $8.26M. LMAT's average Quarter net income forecast represents a 7.72% increase compared to the company's last Quarter net income of $7.50M (Sep 23).
LeMaitre Vascular SG&A Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 3 | 3 | 3 | 3 | 4 | 4 | 4 | 4 | 3 | 6 | 3 | 4 | 7 | 5 | 6 | 3 | 2 | 2 | 2 | 2 | 3 | 4 | 5 | 6 | 11 | 15 | 9 | 9 | 8 | 8 |
| SG&A | - | - | - | - | - | - | - | - | - | - | - | - | - | $17.41M | $17.94M | $18.83M | $15.53M | $15.46M | $15.57M | $15.10M | $14.20M | $12.95M | $13.00M | $13.01M | $11.99M | $11.06M | $10.02M | $13.14M | $12.48M | $11.98M |
| Avg Forecast | $28.37M | $27.49M | $26.63M | $25.80M | $22.46M | $21.53M | $22.48M | $21.48M | $20.48M | $19.79M | $20.34M | $18.93M | $18.13M | $17.59M | $17.79M | $17.21M | $15.17M | $17.40M | $15.31M | $15.64M | $14.67M | $14.45M | $14.64M | $12.53M | $13.16M | $11.70M | $6.34M | $12.26M | $11.26M | $10.42M |
| High Forecast | $28.85M | $27.95M | $27.07M | $26.23M | $22.83M | $21.89M | $22.85M | $21.83M | $20.82M | $20.08M | $20.68M | $22.71M | $18.38M | $17.88M | $18.09M | $20.65M | $15.42M | $20.88M | $15.58M | $18.77M | $14.92M | $14.70M | $14.89M | $15.03M | $13.39M | $11.90M | $6.45M | $14.71M | $11.46M | $10.60M |
| Low Forecast | $27.89M | $27.02M | $26.17M | $25.36M | $22.07M | $21.16M | $22.09M | $21.11M | $20.13M | $19.41M | $19.99M | $15.14M | $18.07M | $17.28M | $17.49M | $13.76M | $14.91M | $13.92M | $14.97M | $12.51M | $14.34M | $14.12M | $14.31M | $10.02M | $12.87M | $11.44M | $6.19M | $9.81M | $11.01M | $10.18M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | 0.99% | 1.01% | 1.09% | 1.02% | 0.89% | 1.02% | 0.97% | 0.97% | 0.90% | 0.89% | 1.04% | 0.91% | 0.95% | 1.58% | 1.07% | 1.11% | 1.15% |
LeMaitre Vascular's average Quarter SG&A projection for Dec 23 is $18.13M, based on 7 Wall Street analysts, with a range of $18.07M to $18.38M. The forecast indicates a 4.14% rise compared to LMAT last annual SG&A of $17.41M (Sep 23).
LeMaitre Vascular EPS Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 3 | 3 | 3 | 3 | 4 | 4 | 4 | 4 | 3 | 6 | 3 | 4 | 7 | 5 | 6 | 3 | 2 | 2 | 2 | 2 | 3 | 4 | 5 | 6 | 11 | 15 | 9 | 9 | 8 | 8 |
| EPS | - | - | - | - | - | - | - | - | - | - | - | - | - | $0.34 | $0.36 | $0.27 | $0.26 | $0.25 | $0.16 | $0.28 | $0.28 | $0.30 | $0.40 | $0.29 | $0.35 | $0.37 | $0.17 | $0.16 | $0.23 | $0.26 |
| Avg Forecast | $0.61 | $0.54 | $0.62 | $0.53 | $0.54 | $0.50 | $0.55 | $0.49 | $0.45 | $0.43 | $0.47 | $0.39 | $0.36 | $0.31 | $0.32 | $0.25 | $0.26 | $0.27 | $0.25 | $0.28 | $0.31 | $0.33 | $0.35 | $0.27 | $0.29 | $0.19 | $0.01 | $0.16 | $0.23 | $0.21 |
| High Forecast | $0.62 | $0.55 | $0.63 | $0.54 | $0.55 | $0.51 | $0.57 | $0.50 | $0.46 | $0.44 | $0.48 | $0.40 | $0.36 | $0.32 | $0.32 | $0.26 | $0.26 | $0.28 | $0.26 | $0.28 | $0.31 | $0.33 | $0.36 | $0.28 | $0.30 | $0.20 | $0.01 | $0.16 | $0.23 | $0.21 |
| Low Forecast | $0.60 | $0.53 | $0.61 | $0.52 | $0.52 | $0.49 | $0.54 | $0.48 | $0.44 | $0.41 | $0.46 | $0.38 | $0.35 | $0.30 | $0.31 | $0.24 | $0.25 | $0.27 | $0.25 | $0.27 | $0.30 | $0.32 | $0.34 | $0.26 | $0.28 | $0.19 | $0.01 | $0.15 | $0.22 | $0.20 |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | 1.10% | 1.14% | 1.08% | 1.02% | 0.92% | 0.63% | 1.01% | 0.91% | 0.92% | 1.14% | 1.07% | 1.19% | 1.91% | 25.50% | 1.01% | 1.01% | 1.25% |
According to 7 Wall Street analysts, LeMaitre Vascular's projected average Quarter EPS for Dec 23 is $0.36, with a low estimate of $0.35 and a high estimate of $0.36. This represents a 4.59% increase compared to LMAT previous annual EPS of $0.34 (Sep 23).
LeMaitre Vascular Peer Comparison by Price Target
| Ticker | Company | Last Closing Price | Avg Price Target | Upside/Downside | Avg Rating |
|---|---|---|---|---|---|
| COO | Cooper Companies | $110.53 | $298.00 | 169.61% | Buy |
| KRMD | KORU Medical Systems | $2.50 | $3.75 | 50.00% | Buy |
| HAE | Haemonetics | $76.09 | $104.33 | 37.11% | Buy |
| NVST | Envista | $19.41 | $23.83 | 22.77% | Hold |
| HOLX | Hologic | $81.15 | $78.92 | -2.75% | Buy |
| LMAT | LeMaitre Vascular | $89.69 | $81.67 | -8.94% | Buy |
| ICUI | ICU Medical | $179.00 | $135.00 | -24.58% | Buy |
LMAT Forecast FAQ
Is LeMaitre Vascular a good buy?
Yes, according to 2 Wall Street analysts, LeMaitre Vascular (LMAT) is considered a 'Buy'. The rating consensus is based on 0 'Strong Buy' and 2 'Buy' recommendations, accounting for 100.00% of LMAT's total ratings.
What is LMAT's price target?
LeMaitre Vascular (LMAT) average price target is $81.67 with a range of $70 to $100, implying a -8.94% from its last price of $89.69. The data is based on 2 Wall Street analysts who provided a twelve-month price target estimate in the last three months.
Will LeMaitre Vascular stock go up soon?
According to Wall Street analysts' prediction for LMAT stock, the company can go down by -8.94% (from the last price of $89.69 to the average price target of $81.67), up by 11.50% based on the highest stock price target, and down by -21.95% based on the lowest stock price target.
Can LeMaitre Vascular stock reach $130?
LMAT's average twelve months analyst stock price target of $81.67 does not support the claim that LeMaitre Vascular can reach $130 in the near future.
What is LeMaitre Vascular's current price target trend?
1 Wall Street analyst forecast a $100 price target for LeMaitre Vascular (LMAT) this month, up 11.50% from its last price of $89.69. Compared to the last 3 and 12 months, the average price target increased by 11.50% and decreased by -2.44%, respectively.
What are LeMaitre Vascular's analysts' financial forecasts?
LeMaitre Vascular's analysts financial forecasts for the fiscal year (Dec 2025) are as follows: average revenue is $237.68M (high $241.63M, low $233.6M), average EBITDA is $50.67M (high $51.51M, low $49.8M), average net income is $47.15M (high $48.17M, low $46.1M), average SG&A $87.94M (high $89.4M, low $86.43M), and average EPS is $2.08 (high $2.12, low $2.03). LMAT's analysts financial forecasts for the fiscal year (Dec 2026) are as follows: average revenue is $292.69M (high $297.55M, low $287.66M), average EBITDA is $62.4M (high $63.43M, low $61.32M), average net income is $52.27M (high $53.4M, low $51.1M), average SG&A $108.29M (high $110.09M, low $106.43M), and average EPS is $2.3 (high $2.35, low $2.25).
Did the LMAT's actual financial results beat the analysts' financial forecasts?
Based on LeMaitre Vascular's last annual report (Dec 2023), the company's revenue was $193.48M, beating the average analysts forecast of $188.16M by 2.83%. Apple's EBITDA was $36.71M, missing the average prediction of $42.77M by -14.16%. The company's net income was $30.1M, beating the average estimation of $29.17M by 3.21%. Apple's SG&A was $72.89M, beating the average forecast of $70.71M by 3.07%. Lastly, the company's EPS was $1.34, beating the average prediction of $1.23 by 8.87%. In terms of the last quarterly report (Sep 2023), LeMaitre Vascular's revenue was $47.41M, missing the average analysts' forecast of $47.53M by -0.25%. The company's EBITDA was $9.37M, missing the average prediction of $10.13M by -7.53%. LeMaitre Vascular's net income was $7.5M, beating the average estimation of $7.02M by 6.92%. The company's SG&A was $17.41M, missing the average forecast of $17.59M by -0.99%. Lastly, the company's EPS was $0.34, beating the average prediction of $0.309 by 10.12%